Totrombopag

DB05930InvestigationalSmall molecule

SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and... This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding, thus representing a significant problem in the...

Primary indication: Investigated for use/treatment in thrombocytopenia.Curator reviewed
Code names: GSK-2285921 · LGD-4665 · SB-559448

Resolves to

Compound

UNII83D6475CAWCAS376592-42-6

Targets

P40238MPL

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

Which drugs share a target with Totrombopag, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account